The Significance of Albuminuria

Slides:



Advertisements
Similar presentations
Dinkar Kaw, M.D., Division of Nephrology
Advertisements

The PREVEND Study: Screening for micro-albuminuria
Ron T. Gansevoort Coordinator PREVEND Study Department of Nephrology University Medical Center Groningen The Netherlands Ron T. Gansevoort Coordinator.
Proteinuria as a Surrogate Outcome in Chronic Kidney Disease Early Diabetes – Microalbuminuria (MA) Type 2 Diabetes in American Indians Robert G Nelson,
National Institute for Health and Clinical Excellence.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
Lesley Stevens MD Tufts-New England Medical Center
Diabetic Nephropathy Case Presentations. UA (Urine Dipstick) Use as an initial screen for all patients Negative to trace proteinuria requires further.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
DECREASING SLEEP-TIME BLOOD PRESSURE DETERMINED BY AMBULATORY MONITORING REDUCES CARDIOVASCULAR RISK Ramón C. Hermida, PhD; Diana E. Ayala, MD, MPH, PhD;
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:
Predicting Progression in Diabetic Nephropathy: New Biomarker: sTNFR1* Circulating soluble Tumor Necrosis Factor Receptor 1.
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
What should the Systolic BP treatment goal be in patients with CKD?
Nephrology Journal Club The SPRINT Trial Parker Gregg
Section 4: Managing progression of CKD
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
HOPE Trial Urine Albumin/Creatinine Ratio (UACR)
Hypertension JNC VIII Guidelines.
Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications  Stefano Bianchi, MD, Roberto Bigazzi, MD, Vito.
Robert C. Stanton, MD  American Journal of Kidney Diseases 
HOPE: Heart Outcomes Prevention Evaluation study
The Anglo Scandinavian Cardiac Outcomes Trial
Copyright © 2015 by the American Osteopathic Association.
Estimated GFR in Diabetes
So What is Albuminuria? An elevated urinary albumin excretion is a marker of endothelial dysfunction that symbolizes the kidney’s way to translate the.
Elevated levels of various circulating amino acids (AAs) predict the development of Type 2 diabetes. In one prospective study, three branched-chain AAs.
RAAS Blockade: Focus on ACEI
The percentage of subjects with de novo development of renal function impairment (GFR
These slides highlight an educational report from a satellite symposium presented at the Annual Scientific Meeting of the Canadian Society of Internal.
The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.
Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?  Sumeet Gupta, MPharm, PhD,
Volume 89, Issue 6, Pages (June 2016)
A: Epidemiology update
Recent studies of ACE inhibition in renal disease
Management of hypertension in patients with chronic kidney disease
Section I: RAS manipulation
These slides highlight a report from a presentation at the European Society of Cardiology 2003 Congress in Vienna Austria, August 30 - September 3, 2003.
Update on Diabetic Nephropathy: Core Curriculum 2018
Hypertension evaluation
Hypertension management in high risk type II diabetes with CKD: Insights from recent trials with a focus on albuminuria. A case based discussion  Matthew.
I. Introduction American Journal of Kidney Diseases
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz 
Robert C. Stanton, MD  American Journal of Kidney Diseases 
American Journal of Kidney Diseases
Update on Diabetic Nephropathy: Core Curriculum 2018
Proteinuria and hypertensive nephrosclerosis in African Americans
Volume 87, Issue 1, Pages (January 2015)
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Volume 53, Issue 6, Pages (June 1998)
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Volume 73, Issue 11, Pages (June 2008)
Presentation transcript:

The Significance of Albuminuria Albuminuria results from injury to glomerular circulation Albuminuria is also an indicator of injury to the systemic circulation Increased albuminuria is associated with progressive kidney disease Increased albuminuria is associated with increased cardiovascular and cerebrovascular risk The Dual Significance of Proteinuria In patients with proteinuric renal diseases the rate of progression of renal insufficiency is determined by the level of blood pressure and proteinuria. The reduction of blood pressure and proteinuria has a beneficial impact on renal risk. Observational studies have also demonstrated that proteinuria is a marker for systemic vascular injury. It is hoped that efforts to reduce proteinuria and control blood pressure will improve cardiovascular risk and reduce mortality. In this belief, the National Kidney Foundation and the American Diabetes Association have revised their recommendations for management of high-risk patients for tighter blood pressure control to <130/80.   References: 1.Treatment of hypertension in patients with diabetes: lessons from recent trials. Cardiol Rev. 2001;9(1):36-44. 2.Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646-661. 3.Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999;34(6):973-995. 4.Proteinuria: its clinical importance and role in progressive renal disease.. Am J Kidney Dis. 2000;35(4suppl1):S97-S105 5.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153. N Engl J Med 2000;342:145-153; Am J Kidney Dis.2000;36:646-661; Am J Kidney Dis 2000;35(4suppl1):S97-S105

Renal Disease and Hypertension- Core Concepts of Treatment Hypertension and albuminuria are both independent variables that predict long-term decline in renal function Renal disease is both a cause and consequence of hypertension Reduction of blood pressure reduces cardiovascular risk and renal risk Reduction of albuminuria lowers both cardiovascular risk and renal risk Renal Disease and Hypertension Core Concepts of Treatment Blood pressure levels are reliable predictors of renal outcome. Both absolute systolic and diastolic blood pressures correlate with the risk of renal damage. African Americans may be at greater risk compared to other racial/ethnic groups. In patients with renal disease, blood pressure reduction clearly effects renal outcome. In both diabetic and non-diabetic patients blood pressure reduction provides greater protection of renal function. The absolute level of blood pressure reduction is important. The initial stages of effective blood pressure control can produce a relative hypoperfusion of the kidneys and a transient increase in serum creatinine. But, clinicians can become alarmed by this rise in serum creatinine and inappropriately withdraw anti-hypertensive therapy rather than waiting several weeks for the serum creatinine to stabilize and/or decline. References: Agarwal R. Treatment of hypertension in patients with diabetes: lessons from recent trials. Cardiol Rev. 2001;9(1):36-44. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646-661. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999;34(6):973-995. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35(4suppl1):S97-S105. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.  Cardiol Rev 2001;9:36-44; Am J Kidney Dis. 1999;34:973-995

Definitions of Microalbuminuria and Macroalbuminuria Measurements of urinary albumin are made from either a timed (4 or 24 hours) urine collection or from a randomly voided “spot” urine. In the former case the urinary albumin concentration is divided by the time of the collection (in minutes) calculate the first parameter. In the latter case, both albumin and creatinine concentrations are measured in the same specimen and a ratio of albumin to creatinine calculated. Numerous studies have demonstrated that the values obtained from both timed and randomly collected specimens correlate well and have the same prognostic significance. Measurements of urine protein concentrations by “dipstick” chemistry are not sufficiently sensitive to identify urine albumin concentrations that meet the criteria for microalbuminuria. Protein in the urine is usually a combination of albumin, globulins, and Tamm-Horsfall protein derived from tubular secretion. References: Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999;34(6):973-995. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35(4suppl1):S97-S105.

The prevalence of microalbuminuria in an aselect sample (n=40,856) of the mostly Caucasian population of 28-75 years in the city of Groningen is 7.2%. Micro-albuminuria was defined as a morning urinary albumin concentration of 20-200 mg/l. Another 16.6% of the population had a borderline albuminuria, or high-normal albuminuria, defined as a urinary albumin concentration of 10-20 mg/L, while 282 subjects had macroalbuminuria. J Int Med 2001;J Int Med 2001;249:519-526.

Of the 2,918 subjects, that were found to be microalbuminuric (defined as a morning urinary albumin concentration of 20-200 mg/L) only 6.2% was known to be diabetic and 18.9% was known to be hypertensive. Although we should realize that insulin using diabetics were not included, this emphasizes that many subjects having microalbuminuria were not known with disorders, traditionally associated with microalbuminuria. J Int Med 2001;249:519-526